629 related articles for article (PubMed ID: 22024310)
1. Olanzapine versus aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a randomized phase III trial.
Navari RM; Gray SE; Kerr AC
J Support Oncol; 2011; 9(5):188-95. PubMed ID: 22024310
[TBL] [Abstract][Full Text] [Related]
2. A phase II trial of olanzapine for the prevention of chemotherapy-induced nausea and vomiting: a Hoosier Oncology Group study.
Navari RM; Einhorn LH; Passik SD; Loehrer PJ; Johnson C; Mayer ML; McClean J; Vinson J; Pletcher W
Support Care Cancer; 2005 Jul; 13(7):529-34. PubMed ID: 15700131
[TBL] [Abstract][Full Text] [Related]
3. Effectiveness of olanzapine in patients who fail therapy with aprepitant while receiving highly emetogenic chemotherapy.
Mehra N; Ganesan P; Ganesan TS; Veeriah S; Boopathy A; Radhakrishnan V; Dhanushkodi M; Rajaraman S; Ganesharajah S; Sagar TG
Med Oncol; 2017 Dec; 35(1):12. PubMed ID: 29248965
[TBL] [Abstract][Full Text] [Related]
4. A randomized phase III study evaluating the efficacy of single-dose NEPA, a fixed antiemetic combination of netupitant and palonosetron, versus an aprepitant regimen for prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving highly emetogenic chemotherapy (HEC).
Zhang L; Lu S; Feng J; Dechaphunkul A; Chang J; Wang D; Chessari S; Lanzarotti C; Jordan K; Aapro M
Ann Oncol; 2018 Feb; 29(2):452-458. PubMed ID: 29092012
[TBL] [Abstract][Full Text] [Related]
5. The use of olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy.
Navari RM; Nagy CK; Gray SE
Support Care Cancer; 2013 Jun; 21(6):1655-63. PubMed ID: 23314603
[TBL] [Abstract][Full Text] [Related]
6. Effectiveness of Antiemetic Regimens for Highly Emetogenic Chemotherapy-Induced Nausea and Vomiting: A Systematic Review and Network Meta-Analysis.
Yokoe T; Hayashida T; Nagayama A; Nakashoji A; Maeda H; Seki T; Takahashi M; Takano T; Abe T; Kitagawa Y
Oncologist; 2019 Jun; 24(6):e347-e357. PubMed ID: 30333194
[TBL] [Abstract][Full Text] [Related]
7. Effectiveness of a single-day three-drug regimen of dexamethasone, palonosetron, and aprepitant for the prevention of acute and delayed nausea and vomiting caused by moderately emetogenic chemotherapy.
Grunberg SM; Dugan M; Muss H; Wood M; Burdette-Radoux S; Weisberg T; Siebel M
Support Care Cancer; 2009 May; 17(5):589-94. PubMed ID: 19037667
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy.
Warr DG; Hesketh PJ; Gralla RJ; Muss HB; Herrstedt J; Eisenberg PD; Raftopoulos H; Grunberg SM; Gabriel M; Rodgers A; Bohidar N; Klinger G; Hustad CM; Horgan KJ; Skobieranda F
J Clin Oncol; 2005 Apr; 23(12):2822-30. PubMed ID: 15837996
[TBL] [Abstract][Full Text] [Related]
9. The oral NK(1) antagonist, aprepitant, given with standard antiemetics provides protection against nausea and vomiting over multiple cycles of cisplatin-based chemotherapy: a combined analysis of two randomised, placebo-controlled phase III clinical trials.
de Wit R; Herrstedt J; Rapoport B; Carides AD; Guoguang-Ma J; Elmer M; Schmidt C; Evans JK; Horgan KJ
Eur J Cancer; 2004 Feb; 40(3):403-10. PubMed ID: 14746859
[TBL] [Abstract][Full Text] [Related]
10. Randomized, double-blind, placebo-controlled study of aprepitant versus two dosages of olanzapine with ondansetron plus dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving high-emetogenic chemotherapy.
Ithimakin S; Theeratrakul P; Laocharoenkiat A; Nimmannit A; Akewanlop C; Soparattanapaisarn N; Techawattanawanna S; Korphaisarn K; Danchaivijitr P
Support Care Cancer; 2020 Nov; 28(11):5335-5342. PubMed ID: 32128615
[TBL] [Abstract][Full Text] [Related]
11. Metoclopramide, Dexamethasone, or Palonosetron for Prevention of Delayed Chemotherapy-Induced Nausea and Vomiting After Moderately Emetogenic Chemotherapy (MEDEA): A Randomized, Phase III, Noninferiority Trial.
van der Vorst MJDL; Toffoli EC; Beusink M; van Linde ME; van Voorthuizen T; Brouwer S; van Zweeden AA; Vrijaldenhoven S; Berends JC; Berkhof J; Verheul HMW
Oncologist; 2021 Jan; 26(1):e173-e181. PubMed ID: 32735029
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of NEPA, a fixed antiemetic combination of netupitant and palonosetron, vs a 3-day aprepitant regimen for prevention of chemotherapy-induced nausea and vomiting (CINV) in Chinese patients receiving highly emetogenic chemotherapy (HEC) in a randomized Phase 3 study.
Chang J; Chen G; Wang D; Wang G; Lu S; Feng J; Li W; Li P; Lanzarotti C; Chessari S; Zhang L
Cancer Med; 2020 Jul; 9(14):5134-5142. PubMed ID: 32472742
[TBL] [Abstract][Full Text] [Related]
13. The oral NK(1) antagonist aprepitant for the prevention of acute and delayed chemotherapy-induced nausea and vomiting: Pooled data from 2 randomised, double-blind, placebo controlled trials.
Warr DG; Grunberg SM; Gralla RJ; Hesketh PJ; Roila F; Wit Rd; Carides AD; Taylor A; Evans JK; Horgan KJ
Eur J Cancer; 2005 Jun; 41(9):1278-85. PubMed ID: 15939263
[TBL] [Abstract][Full Text] [Related]
14. Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomised, comparative phase III trial.
Saito M; Aogi K; Sekine I; Yoshizawa H; Yanagita Y; Sakai H; Inoue K; Kitagawa C; Ogura T; Mitsuhashi S
Lancet Oncol; 2009 Feb; 10(2):115-24. PubMed ID: 19135415
[TBL] [Abstract][Full Text] [Related]
15. A phase II trial of olanzapine, dexamethasone, and palonosetron for the prevention of chemotherapy-induced nausea and vomiting: a Hoosier oncology group study.
Navari RM; Einhorn LH; Loehrer PJ; Passik SD; Vinson J; McClean J; Chowhan N; Hanna NH; Johnson CS
Support Care Cancer; 2007 Nov; 15(11):1285. PubMed ID: 17375339
[TBL] [Abstract][Full Text] [Related]
16. The Efficacy, Safety, and Cost Benefit of Olanzapine versus Aprepitant in Highly Emetogenic Chemotherapy: A Pilot Study from South India.
Babu G; Saldanha SC; Kuntegowdanahalli Chinnagiriyappa L; Jacob LA; Mallekavu SB; Dasappa L; Kiran PR; Sreevatsa A; Appachu S; Unnikrishnan V; Arroju V
Chemother Res Pract; 2016; 2016():3439707. PubMed ID: 26925265
[TBL] [Abstract][Full Text] [Related]
17. Dexamethasone-Free Antiemetic Prophylaxis for Highly Emetogenic Chemotherapy: A Double-Blind, Phase III Randomized Controlled Trial (CINV POD study).
Radhakrishnan V; Venkatakrishnan K; Perumal Kalaiyarasi J; Selvarajan G; Mahaboobasha N; Victor PV; Anbazhagan M; Sivanandam DM; Rajaraman S
JCO Glob Oncol; 2024 Jan; 10():e2300301. PubMed ID: 38237092
[TBL] [Abstract][Full Text] [Related]
18. Incidence of chemotherapy-induced nausea and vomiting associated with docetaxel and cyclophosphamide in early breast cancer patients and aprepitant efficacy as salvage therapy. Results from the Spanish Breast Cancer Group/2009-02 study.
Llombart-Cussac A; Ramos M; Dalmau E; García-Saenz JA; González-Farré X; Murillo L; Calvo L; Morales S; Carañana V; González A; Fernández-Morales LA; Moreno F; Casas MI; Angulo Mdel M; Cámara MC; Garcia-Mace AI; Carrasco E; Jara-Sánchez C
Eur J Cancer; 2016 May; 58():122-9. PubMed ID: 26994459
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and emesis over multiple cycles of moderately emetogenic chemotherapy.
Herrstedt J; Muss HB; Warr DG; Hesketh PJ; Eisenberg PD; Raftopoulos H; Grunberg SM; Gabriel M; Rodgers A; Hustad CM; Horgan KJ; Skobieranda F;
Cancer; 2005 Oct; 104(7):1548-55. PubMed ID: 16104039
[TBL] [Abstract][Full Text] [Related]
20. Pathogenesis-based treatment of chemotherapy-induced nausea and vomiting--two new agents.
Navari RM
J Support Oncol; 2003; 1(2):89-103. PubMed ID: 15352652
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
